Prashant
2021-10-26
This approval will embark the commencement of new era for Indian Pharma sector .
Ocugen stock surged 33% in extended trading
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":856552243,"tweetId":"856552243","gmtCreate":1635204497698,"gmtModify":1635204525065,"author":{"id":3569291088297790,"idStr":"3569291088297790","authorId":3569291088297790,"authorIdStr":"3569291088297790","name":"Prashant","avatar":"https://static.tigerbbs.com/d8814671cf4887208a8404f7fc63d9fd","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":18,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>This approval will embark the commencement of new era for Indian Pharma sector .</p><p><br></p></body></html>","htmlText":"<html><head></head><body><p>This approval will embark the commencement of new era for Indian Pharma sector .</p><p><br></p></body></html>","text":"This approval will embark the commencement of new era for Indian Pharma sector .","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/856552243","repostId":1134394285,"repostType":4,"repost":{"id":"1134394285","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635204261,"share":"https://www.laohu8.com/m/news/1134394285?lang=&edition=full","pubTime":"2021-10-26 07:24","market":"us","language":"en","title":"Ocugen stock surged 33% in extended trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1134394285","media":"Tiger Newspress","summary":"Ocugen stock surged 33% in extended trading as the WHO expert group will meet on Tuesday to approve ","content":"<p>Ocugen stock surged 33% in extended trading as the WHO expert group will meet on Tuesday to approve EUA of COVID-19 vaccine covaxin in cooperation with India.</p>\n<p><img src=\"https://static.tigerbbs.com/75ccaedccac7e3cc601730bb5fa6da04\" tg-width=\"849\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>Ocugen shares are rising in the post-market ahead of a meeting by an advisory panel of The World Health Organisation (WHO) on Tuesday to discuss whether to grant an emergency use listing for its partner’s COVID-19 vaccine named Covaxin.</p>\n<p>WHO will make a decision on the vaccine developed by Bharat Biotech based on the recommendations of the Technical Advisory Group.</p>\n<p>Social media is abuzz with speculation that the WHO has already greenlighted the vaccine as the global body has posted on its website several documents related to the vaccine ahead of the meeting.</p>\n<p>Ocugen (OCGN) partnered with Bharat Biotech to co-develop Covaxin for the U.S. market, and in late-stage trials, it has shown about 78% efficacy against COVID-19.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen stock surged 33% in extended trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen stock surged 33% in extended trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-26 07:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ocugen stock surged 33% in extended trading as the WHO expert group will meet on Tuesday to approve EUA of COVID-19 vaccine covaxin in cooperation with India.</p>\n<p><img src=\"https://static.tigerbbs.com/75ccaedccac7e3cc601730bb5fa6da04\" tg-width=\"849\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>Ocugen shares are rising in the post-market ahead of a meeting by an advisory panel of The World Health Organisation (WHO) on Tuesday to discuss whether to grant an emergency use listing for its partner’s COVID-19 vaccine named Covaxin.</p>\n<p>WHO will make a decision on the vaccine developed by Bharat Biotech based on the recommendations of the Technical Advisory Group.</p>\n<p>Social media is abuzz with speculation that the WHO has already greenlighted the vaccine as the global body has posted on its website several documents related to the vaccine ahead of the meeting.</p>\n<p>Ocugen (OCGN) partnered with Bharat Biotech to co-develop Covaxin for the U.S. market, and in late-stage trials, it has shown about 78% efficacy against COVID-19.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134394285","content_text":"Ocugen stock surged 33% in extended trading as the WHO expert group will meet on Tuesday to approve EUA of COVID-19 vaccine covaxin in cooperation with India.\n\nOcugen shares are rising in the post-market ahead of a meeting by an advisory panel of The World Health Organisation (WHO) on Tuesday to discuss whether to grant an emergency use listing for its partner’s COVID-19 vaccine named Covaxin.\nWHO will make a decision on the vaccine developed by Bharat Biotech based on the recommendations of the Technical Advisory Group.\nSocial media is abuzz with speculation that the WHO has already greenlighted the vaccine as the global body has posted on its website several documents related to the vaccine ahead of the meeting.\nOcugen (OCGN) partnered with Bharat Biotech to co-develop Covaxin for the U.S. market, and in late-stage trials, it has shown about 78% efficacy against COVID-19.","news_type":1},"isVote":1,"tweetType":1,"viewCount":272,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":67,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/856552243"}
精彩评论